share_log

Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis

Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis

Blueprint Medicines報告歐洲藥品管理局對AYVAKYT公司治療晚期系統性肥大細胞增多症的2型變異營銷授權申請的驗證
Benzinga Real-time News ·  2021/03/03 21:04

Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis

Blueprint Medicines報告歐洲藥品管理局對AYVAKYT公司治療晚期系統性肥大細胞增多症的2型變異營銷授權申請的驗證

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論